• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PVLA

    Palvella Therapeutics Inc.

    Subscribe to $PVLA
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Palvella Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    9/9/2025$85.00Outperform
    Oppenheimer
    8/6/2025$54.00Outperform
    Raymond James
    7/21/2025$56.00Buy
    Truist
    4/9/2025$50.00Buy
    Chardan Capital Markets
    3/26/2025$45.00Buy
    Stifel
    3/7/2025$50.00Sector Outperform
    Scotiabank
    2/20/2025$39.00Buy
    Canaccord Genuity
    2/5/2025$44.00Buy
    TD Cowen
    12/26/2024$38.00Buy
    H.C. Wainwright
    12/18/2024Overweight
    Cantor Fitzgerald
    See more ratings

    Palvella Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wessel Tadd S.

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 8:00:08 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kiritsy Christopher P

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 7:59:56 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Jenkins George M

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 7:59:46 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Heron Elaine J

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 7:59:36 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Davis Todd C

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 7:59:24 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Kline Ashley Hartmann

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/3/25 9:15:01 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Kline Ashley Hartmann

    3 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/3/25 9:08:23 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/10/25 7:06:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by President and CEO Kaupinen Wes

    4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    2/10/25 6:25:31 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Chief Scientific Officer Martini Jeffrey S

    4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    2/10/25 6:00:29 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/10/25 7:06:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins George M bought $51,720 worth of shares (4,000 units at $12.93), increasing direct ownership by 2% to 180,671 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    12/19/24 10:23:28 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Palvella Therapeutics with a new price target

    Oppenheimer initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $85.00

    9/9/25 7:43:25 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Palvella Therapeutics with a new price target

    Raymond James initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $54.00

    8/6/25 8:01:45 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Palvella Therapeutics with a new price target

    Truist initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $56.00

    7/21/25 8:38:19 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Palvella Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $50.00

    4/9/25 7:50:47 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Palvella Therapeutics with a new price target

    Stifel initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $45.00

    3/26/25 7:50:34 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Palvella Therapeutics with a new price target

    Scotiabank initiated coverage of Palvella Therapeutics with a rating of Sector Outperform and set a new price target of $50.00

    3/7/25 8:18:07 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Palvella Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $39.00

    2/20/25 7:05:42 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Palvella Therapeutics with a new price target

    TD Cowen initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $44.00

    2/5/25 7:03:25 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Palvella Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $38.00

    12/26/24 7:16:05 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Palvella Therapeutics

    Cantor Fitzgerald initiated coverage of Palvella Therapeutics with a rating of Overweight

    12/18/24 8:31:22 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. SEC Filings

    View All

    Palvella Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    9/24/25 6:01:02 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    9/3/25 7:31:18 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Palvella Therapeutics Inc.

    10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    8/14/25 8:00:14 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    8/14/25 7:30:14 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    6/11/25 4:05:57 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Palvella Therapeutics Inc.

    10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    5/15/25 7:45:33 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    5/15/25 7:31:32 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Palvella Therapeutics Inc.

    DEFA14A - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    4/30/25 4:08:36 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Palvella Therapeutics Inc.

    DEF 14A - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    4/30/25 4:05:59 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Palvella Therapeutics Inc.

    10-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    3/31/25 7:51:15 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

    Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients Company plans to initiate a Phase 2 trial evaluating QTORIN™ rapamycin for clinically significant angiokeratomas in the second half of 2026 Company to host webcast conference call today, September 24, 2025 at 8:30am ET WAYNE, Pa., Sept. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suff

    9/24/25 6:00:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

    Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includes a systematic review of 26 studies evaluating the use of rapamycin for the treatment of venous malformations Study authors highlight unmet clinical need for venous malformations and lack of FDA-approved pharmacologic options while advocating for an FDA-approved targeted topical formulation of rapamycin for patients with cutaneous venous malformations WAYNE, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeu

    9/17/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

    Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common type of vascular malformation, with skin involvement impacting an estimated approximately 50-80% of patients, which can result in bleeding, thrombosis, ulceration, disfigurement, and proliferation QTORIN™ rapamycin has the potential to be the first approved therapy in the U.S. for more than an estimated 75,000 U.S. patients with cutaneous VMs WAYNE, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceut

    9/15/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

    WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows: Cantor Global Healthcare ConferenceThursday, September 4, 2025, at 2:45pm ET H.C. Wainwright 27th Annual Global Investment ConferenceMonday, September 8, 2025, at 10:30am ET A liv

    8/28/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line results for Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations Company plans to announce both a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ p

    8/14/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

    WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events

    8/7/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

    WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palve

    8/5/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

    WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000® Index and the Russell 2000® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. Annual Russell indexes reconstitution captures the 3,000 largest US stocks, ranking them by total market capitalization. Membership in the

    6/30/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

    Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies Top-line data expected in the first quarter of 2026 WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the successful completion of SELVA, a Phase 3 trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatme

    6/23/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

    Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability WAYNE, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing an

    5/27/25 8:00:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. Financials

    Live finance-specific insights

    View All

    Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

    Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients Company plans to initiate a Phase 2 trial evaluating QTORIN™ rapamycin for clinically significant angiokeratomas in the second half of 2026 Company to host webcast conference call today, September 24, 2025 at 8:30am ET WAYNE, Pa., Sept. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suff

    9/24/25 6:00:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line results for Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations Company plans to announce both a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ p

    8/14/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

    WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events

    8/7/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous venous malformations Cash and cash equivalents of $75.6 million as of Ma

    5/15/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

    WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, May 15, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" se

    5/8/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

    Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

    3/31/25 7:30:00 AM ET
    $LGND
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

    WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" sect

    3/18/25 8:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care